<DOC>
	<DOCNO>NCT00022308</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy radiation therapy may kill tumor cell . PURPOSE : Phase I trial study effectiveness combination chemotherapy radiation therapy treat patient locally advance non-small cell lung cancer .</brief_summary>
	<brief_title>Chemotherapy Radiation Therapy Treating Patients With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose irinotecan administer cisplatin radiotherapy patient locally advance non-small cell lung carcinoma . II . Determine toxic effect , especially acute long-term esophagitis pneumonitis , regimen patient . III . Determine response rate , duration progression , sit relapse patient treat regimen . OUTLINE : This multicenter , dose-escalation study irinotecan . Patients receive irinotecan IV 90 minute cisplatin 1 hour day 1 . Patients also undergo radiotherapy daily day 1-5 . Treatment repeat every 7 day 7 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos irinotecan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow every 2 month 1 year , every 3 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : Approximately 3-27 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) Stage IIIB bulky stage IIIA amenable surgical resection Medically inoperable stage II nonbulky stage IIIA Locally recurrent disease follow surgery amenable surgical resection No small cell carcinoma mixed cytology No disease beyond radiation portal ( T4 tumor document multifocal malignant pleural involvement extension supraclavicular nodal disease cervical chain ) No pleural effusion Pleural effusion visible CT scan chest xray inaccessible thoracentesis cytologically negative allow Ineligible enrollment protocol RTOG 9309 PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Karnofsky 50100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 2,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL No known Gilbert 's disease Renal : Creatinine great 1.5 mg/dL Calcium le 12.0 mg/dL Cardiovascular : No symptomatic cardiovascular disease No active angina No congestive heart failure require active therapy No uncontrolled arrhythmias No myocardial infarction within past 6 month Pulmonary : FEV1 least 1.0 L unless clear radiation oncologist Other : Not pregnant Negative pregnancy test Fertile patient must use effective contraception 3 month study , study , 3 month study HIV negative No concurrent active invasive malignancy except nonmelanoma skin cancer Less 10 % unintended weight loss within 3 month diagnosis No concurrent medical condition would preclude study No social situation psychiatric disorder would preclude study No active uncontrolled infection No history seizures No uncontrolled diabetes mellitus ( random blood sugar least 250 mg/dL ) PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy NSCLC No prior irinotecan topotecan Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy NSCLC No prior radiotherapy chest Surgery : See Disease Characteristics Other : No concurrent phenytoin , phenobarbital , antiepileptic prophylaxis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>